Press Release: New data at AAN reinforce Novartis -2-

regarding potential marketing approvals, new indications or labeling for

the investigational or approved products described in this press release,

or regarding potential future revenues from such products or the

collaboration with Amgen. You should not place undue reliance on these

statements. Such forward-looking statements are based on our current

beliefs and expectations regarding future events, and are subject to

significant known and unknown risks and uncertainties. Should one or

more of these risks or uncertainties materialize, or should underlying

assumptions prove incorrect, actual results may vary materially from

those set forth in the forward-looking statements. There can be no

guarantee that the investigational or approved products described in

this press release will be submitted or approved for sale or for any

additional indications or labeling in any market, or at any particular

time. Neither can there be any guarantee that the collaboration with

Amgen will achieve any or all of its intended goals, or within any

particular time frame. Nor can there be any guarantee that such products

or the collaboration with Amgen will be commercially successful in the

future. In particular, our expectations regarding such products and the

collaboration with Amgen could be affected by, among other things, the

uncertainties inherent in research and development, including clinical

trial results and additional analysis of existing clinical data;

regulatory actions or delays or government regulation generally; global

trends toward health care cost containment, including government, payor

and general public pricing and reimbursement pressures and requirements

for increased pricing transparency; our ability to obtain or maintain

proprietary intellectual property protection; the outcome of litigation

and legal disputes, including the legal dispute with Amgen regarding our

collaboration agreements in the field of migraine; the particular

prescribing preferences of physicians and patients; general political

and economic conditions; safety, quality or manufacturing issues;

potential or actual data security and data privacy breaches, or

disruptions of our information technology systems, and other risks and

factors referred to in Novartis AG's current Form 20-F on file with the

US Securities and Exchange Commission. Novartis is providing the

information in this press release as of this date and does not undertake

any obligation to update any forward-looking statements contained in

this press release as a result of new information, future events or

otherwise.

*The brand name Zolgensma has been provisionally approved by the FDA for

the investigational product AVXS-101 (onasemnogene abeparvovec-xioi),

but the product itself has not received marketing authorization or BLA

approval from any regulatory authorities.

About Novartis

Novartis is reimagining medicine to improve and extend people's lives.

As a leading global medicines company, we use innovative science and

digital technologies to create transformative treatments in areas of

great medical need. In our quest to find new medicines, we consistently

rank among the world's top companies investing in research and

development. Novartis products reach more than 750 million people

globally and we are finding innovative ways to expand access to our

latest treatments. About 105 000 people of more than 140 nationalities

work at Novartis around the world. Find out more at www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at

http://twitter.com/novartis

For Novartis multimedia content, please visit

www.novartis.com/news/media-library

For questions about the site or required registration, please contact

media.relations@novartis.com

References

[1] Dabbous O, et al. Event-Free Survival and Motor Milestone

Achievement Following AVXS-101 and Nusinersen Interventions Contrasted

to Natural History for Type I Spinal Muscular Atrophy Patients. Oral

presentation. 2019 AAN.

[2] Dabbous O, et al. The Value of AVXS-101 Gene Replacement Therapy

for Spinal Muscular Atrophy Type 1: Improved Survival, Pulmonary and

Nutritional Support, and Motor Function with Decreased Hospitalization.

Poster Presentation. 2019 AAN.

[3] Day J, et al. AVXS-101 Gene-Replacement Therapy (GRT) for Spinal

Muscular Atrophy Type 1 (SMA1): Pivotal Phase 3 Study (STR1VE) Update.

Poster presentation. 2019 AAN.

[4] Droege M, et al. Number Needed to Treat (NNT) in Spinal Muscular

Atrophy Type 1 (SMA1) with AVXS-101 Relative to Nusinersen. Poster

presentation. 2019 AAN.

[5] Droege M, et al. Early Diagnosis and Speed to Effect in Spinal

Muscular Atrophy Type 1 (SMA1). Oral presentation. 2019 AAN.

[6] Finkel R, et al. Phase 1 Study of Intrathecal Administration of

AVXS-101 Gene-Replacement Therapy (GRT) for Spinal Muscular Atrophy Type

2 (SMA2) (STRONG). Poster presentation. 2019 AAN.

[7] Leonard H, et al. Establishing Clinical Trial Readiness of the

Rett Syndrome Hand Function Measure. Poster presentation. 2019 AAN.

[8] Mendell J, et al. AVXS-101 Gene-Replacement Therapy (GRT) in

Spinal Muscular Atrophy Type 1 (SMA1): Long-Term Follow-Up From the

Phase 1 Clinical Trial. Oral presentation. 2019 AAN.

[9] Powers S, et al. Rett syndrome gene therapy improves survival and

ameliorates behavioral phenotypes in MeCP2 null. Oral presentation. 2019

AAN.

[10] Schultz M, et al. AVXS-101 Gene-Replacement Therapy (GRT) in

Presymptomatic Spinal Muscular Atrophy (SMA): Study Update. Poster

presentation. 2019 AAN.

[11] Thomsen G, et al. Intrathecal AAV9-SOD1-shRNA Administration for

Amyotrophic Lateral Sclerosis. Oral presentation. 2019 AAN.

[12] Deconinck N, et al. Serum Neurofilament Light Chain as a Potential

Biomarker for Spinal Muscular Atrophy Type I Disease Activity and

Therapy Response. Oral presentation. 2019 AAN.

[13] Benedict R, Fox R, Tomic D, et al. Effect of Siponimod on

Cognition in Patients with Secondary Progressive Multiple Sclerosis

(SPMS): Phase 3 EXPAND Study Subgroup Analysis. Poster presentation.

2019 AAN.

[14] Reuter U, et al. Assessment of the Efficacy of Erenumab During the

Open-Label Treatment (13-24 Weeks) of Subjects with Episodic Migraine

Who Failed 2-4 Prior Preventive Treatments: Results of the LIBERTY

Study. Poster presentation. 2019 AAN.

[15] Reuter U, et al. Long-term Efficacy of Erenumab in Patients With

Episodic Migraine Who Have Failed Prior Preventive Migraine Therapies.

Poster presentation. 2019 AAN.

[16] Tepper S, et al. Assessment of the Long-Term Safety and Efficacy

of Erenumab During Open-Label Treatment of Patients With Chronic

Migraine. Poster presentation. 2019 AAN.

[17] Lipton R, et al. Efficacy of erenumab in chronic migraine patients

with and without allodynia. Poster presentation. 2019 AAN.

[18] Lipton R, et al. Conversion from Chronic migraine to episodic

migraine with long term erenumab treatment. Oral presentation. 2019 AAN.

[19] Ohlsson L, et al. Erenumab (AMG334) An Antagonist to Canonical

CGRP-Receptor Does Not Impair Vasodilatory or Contractile Responses to

Other Agents In Human Isolated Cerebral Arteries. Oral presentation.

2019 AAN.

[20] Dodick D, et al. Efficacy of erenumab in chronic migraine patients

with medication overuse and prior preventive treatment failure. Oral

presentation. 2019 AAN.

[21] Chou D, et al. Sustained Efficacy Over 1 Year of Treatment With

Erenumab: Results From the Extension Phase of the STRIVE Study in

Episodic Migraine. Oral presentation. 2019 AAN.

[22] Schaetz L, et al. Healthcare Expenditure in Migraine Compared to

Other Leading Causes of Disability: Adequate or Not? Poster

presentation. 2019 AAN.

[23] Rahn K, Slusher B, and Kaplin, A. Cognitive Impairment in Multiple

Sclerosis: A Forgotten Disibility Remembered. The Dana Foundation.

http://www.dana.org/Cerebrum/2012/Cognitive_Impairment_in_Multiple_Sclerosis__A_Forgotten_Disability_Remembered/.

Accessed April 2019.

[24] Cree B, Goldman M, Corboy J, et al. Efficacy and safety of

fingolimod 0.5 mg and 0.25 mg versus glatiramer acetate 20 mg in

patients with relapsing-remitting multiple sclerosis - ASSESS Study

Group. Poster presentation. 2019 AAN.

[25] Ziemssen T, et al. Validation of the Scoring Algorithm for a Novel

Integrative Secondary Progressive Multiple Sclerosis (SPMS) Screening

Tool. Poster presentation. 2019 AAN.

[26] Dawson J, et al. Effect of Subcutaneous Treatment With Anti-CD20

Antibody on B-cell Depletion in a Lipopolysaccharide-Induced

Inflammatory Mouse Model. Poster presentation. 2019 AAN.

[27] Kappos L, et al. Baseline Characteristics of Patients with

Relapsing Multiple Sclerosis in ASCLEPIOS Phase 3 Trials of Ofatumumab

Versus Teriflunomide. Poster Presentation. 2019 AAN.

[28] Migotto M, et al. Effect of Route of Administration on the

Biodistribution of a Novel Anti-CD20 Antibody in Experimental Autoimmune

Encephalomyelitis-Variant Mice. 2019 AAN.

[29] Torres J, et al. Distribution and Efficacy of Ofatumumab and

Ocrelizumab in Humanized-CD20 Mice following Subcutaneous or Intravenous

Administration. Poster presentation. 2019 AAN.

[30] Kuhle J, et al. The Predictive Value of Neurofilament Light Chain

Levels in Blood for Cognitive Impairment in Patients with Secondary

Progressive Multiple Sclerosis. Oral presentation. 2019 AAN.

[31] Kuhle J, et al. An Integral Measure of Serial Neurofilament Light

Chain Assessments in Blood is a Predictor of Long-Term Disability

Progression in Relapsing-Remitting Multiple Sclerosis. 2018 ECTRIMS.

[32] Kappos L. Neurofilament Light Levels in the Blood of Patients with

Secondary Progressive MS are higher than in Primary Progressive MS and

may Predict Brain Atrophy in both MS Subtypes. Oral presentation. 2018

ECTRIMS.

[33] Reinert M, et al. Neurofilament Light Chain is a Useful Biomarker

in Paediatric Multiple Sclerosis. 2018 ECTRIMS.

(MORE TO FOLLOW) Dow Jones Newswires

April 30, 2019 16:30 ET (20:30 GMT)